PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32624703-0 2020 Berberine Inhibits Pro-inflammatory Cytokine-induced IL-6 and CCL11 Production via Modulation of STAT6 Pathway in Human Bronchial Epithelial Cells. Berberine 0-9 interleukin 6 Homo sapiens 53-57 32857851-0 2020 Berberine functions as a negative regulator in lipopolysaccharide -induced sepsis by suppressing NF-kappaB and IL-6 mediated STAT3 activation. Berberine 0-9 interleukin 6 Homo sapiens 111-115 32857851-9 2020 We further found that berberine inhibited the expression of tumor necrosis factor (TNF)-alpha, interleukin-(IL)-1beta, and IL-6 via suppressing nuclear factor kappa B subunit 1 (NF-kappaB) signaling activation. Berberine 22-31 interleukin 6 Homo sapiens 123-127 31412862-6 2019 BBR also caused a marked reduction in the secretion of proinflammatory cytokines, Interleukin-1alpha (IL-1alpha), Interleukin-1beta (IL-1beta), Interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha). Berberine 0-3 interleukin 6 Homo sapiens 144-157 31412862-6 2019 BBR also caused a marked reduction in the secretion of proinflammatory cytokines, Interleukin-1alpha (IL-1alpha), Interleukin-1beta (IL-1beta), Interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha). Berberine 0-3 interleukin 6 Homo sapiens 159-163 33496116-9 2020 The results of molecular docking showed that baicalein,berberine,licochalcone A and 6-gingerol had a high affinity with SRC,STAT3,TNF and IL6. Berberine 55-64 interleukin 6 Homo sapiens 138-141 34968467-0 2022 Berberine inhibits gastric cancer development and progression by regulating the JAK2/STAT3 pathway and downregulating IL-6. Berberine 0-9 interleukin 6 Homo sapiens 118-122 34968467-10 2022 Mechanistically, these findings imply that BBR inhibits GC cell proliferation by modulating the signaling pathways related to IL-6/JAK2/STAT3. Berberine 43-46 interleukin 6 Homo sapiens 126-130 34493195-7 2022 RESULTS: We filtered out 6 pivotal ingredients from QFPDD by using the bioinformatics method, namely quercetin, luteolin, berberine, hederagenin, shionone and kaempferol, which can inhibit the highly expressed genes (i.e. CXCR4, ICAM1, CXCL8, CXCL10, IL6, IL2, CCL2, IL1B, IL4, IFNG) in severe COVID-19 patients. Berberine 122-131 interleukin 6 Homo sapiens 251-254 34443321-5 2021 AA/ LPS-induced TNF-alpha, MCP-1, IL-6, IL-8, and COX-2 markers were markedly attenuated by BBR treatment in THP-1 cells by inhibiting NF-kappaB translocation into the nucleus. Berberine 92-95 interleukin 6 Homo sapiens 34-38 34467691-5 2021 The results revealed that the main compounds of Euodiae Fructus, such as berberine and rutaecarpine, participated in the biological processes(such as neurotransmitter receptor activity) by regulating C-reactive protein(CRP), estrogen receptor 1(ESR1), 5-hydroxytryptamine(5-HT) receptor, and interleukin-6(IL-6) to exert sedative, anxiolytic, and antidepressant effects. Berberine 73-82 interleukin 6 Homo sapiens 306-310 32624703-10 2020 Berberine significantly inhibited the secretion of IL-6 and CCL11 from pro-inflammatory cytokine-activated BEAS-2B cells. Berberine 0-9 interleukin 6 Homo sapiens 51-55 32624703-13 2020 Current study reveals that berberine has inhibitory effect in pro-inflammatory cytokine-activated BEAS-2B cells through reducing IL-6 and CCL11 production, which is possibly modulated by suppressing STAT6 signaling pathway. Berberine 27-36 interleukin 6 Homo sapiens 129-133 31781264-7 2019 Berberine remarkably inhibited the proliferation and the excessive production of IL-6 and TNF-alpha in FLS-RA, whereas suppressing the expression of K-ras, c-Raf, and p-38/ERK-phosphorylation. Berberine 0-9 interleukin 6 Homo sapiens 81-85 32258115-7 2020 With the cotreatment with LPS, which could boost the expression of cytokines in these cancer cells, berberine significantly reduced the increased expression of TNF-alpha and IL-6. Berberine 100-109 interleukin 6 Homo sapiens 174-178 31837588-11 2020 BBR (25 uM) treatment in LPS-HDPF could ameliorate cell inflammatory response, presented by reduced expressions of IL-1beta, IL-6 and TNF-alpha, as well as enhanced cell proliferation and miR-21 expression. Berberine 0-3 interleukin 6 Homo sapiens 125-129 24380387-8 2013 In vitro, berberine inhibited both constitutive and IL-6-induced STAT3 activation in NPC cells. Berberine 10-19 interleukin 6 Homo sapiens 52-56 30021340-12 2018 in vivo, berberine significantly reduced the levels of CRP, TNF-alpha and IL-6 in the patients" plasma. Berberine 9-18 interleukin 6 Homo sapiens 74-78 28929697-12 2016 This study showed that berberine in addition to the general therapy can significantly lower the levels of serum MIF and IL-6, reduce the degree of carotid atherosclerosis to some extent and improve neurological impairment and the prognosis of patients with AIS. Berberine 23-32 interleukin 6 Homo sapiens 120-124 27045865-14 2016 CONCLUSIONS: Berberine, baicalin and geniposide could neutralize LPS by binding with lipid A and then reduce the release of IL-6 and TNF-alpha induced by LPS. Berberine 13-22 interleukin 6 Homo sapiens 124-128 19034703-0 2008 Berberine inhibits the expression of TNFalpha, MCP-1, and IL-6 in AcLDL-stimulated macrophages through PPARgamma pathway. Berberine 0-9 interleukin 6 Homo sapiens 58-62 23247593-6 2013 RESULTS: Treatment of U266 cells with berberine (40-160 mumol/L) suppressed cell proliferation and IL-6 secretion in dose- and time-dependent manners. Berberine 38-47 interleukin 6 Homo sapiens 99-103 23247593-8 2013 Overexpression of miR-21 counteracted berberine-induced suppression of cell proliferation and IL-6 secretion. Berberine 38-47 interleukin 6 Homo sapiens 94-98 21110076-5 2011 Berberine effectively inhibited IL-6 and TNF-alpha production in a concentration-dependent manner, demonstrating its anti-inflammatory activity in hepatocytes. Berberine 0-9 interleukin 6 Homo sapiens 32-36 19034703-8 2008 This study demonstrates that berberine may inhibit the expression and production of TNF-alpha, MCP-1, and IL-6 in AcLDL-stimulated macrophages. Berberine 29-38 interleukin 6 Homo sapiens 106-110 19034703-6 2008 In this study, we investigated the effects and the mechanism of action of berberine on the expression and secretion of TNFalpha, MCP-1, and IL-6 in vitro to identify new pharmacological actions of berberine. Berberine 74-83 interleukin 6 Homo sapiens 140-144 19034703-7 2008 The results of RT-PCR and ELISA shows that berberine may inhibit the expression and secretion of the tumor necrosis factor alpha (TNFalpha), monocyte chemoattractant protein 1 (MCP-1), and interleukin-6 (IL-6) in macrophages stimulated by acetylated low-density lipoprotein (AcLDL), whereas the peroxisome proliferator-activated receptor gamma (PPARgamma) inhibitor GW9662 could attenuate this effect of berberine. Berberine 43-52 interleukin 6 Homo sapiens 189-202 19034703-7 2008 The results of RT-PCR and ELISA shows that berberine may inhibit the expression and secretion of the tumor necrosis factor alpha (TNFalpha), monocyte chemoattractant protein 1 (MCP-1), and interleukin-6 (IL-6) in macrophages stimulated by acetylated low-density lipoprotein (AcLDL), whereas the peroxisome proliferator-activated receptor gamma (PPARgamma) inhibitor GW9662 could attenuate this effect of berberine. Berberine 43-52 interleukin 6 Homo sapiens 204-208 17951041-0 2008 Berberine inhibits TPA-induced MMP-9 and IL-6 expression in normal human keratinocytes. Berberine 0-9 interleukin 6 Homo sapiens 41-45 17951041-4 2008 Our results demonstrated that berberine dose-dependently inhibited basal and TPA-induced expression and activity of MMP-9, and also suppressed TPA-induced IL-6 expression. Berberine 30-39 interleukin 6 Homo sapiens 155-159